Patterns of use, clinical efficacy, safety and tolerability of Ketamine and Esketamine in treatment-resistant depression: Towards registry-based surveillance systems.

More data on the long-term effects of Racemic Ketamine and Esketamine in TDR patients is needed. The implementation of centralized registries of their use for treatment of depression could be a tool of major importance for assessing their efficacy and safety in real-world clinical practice. This paper seeks to outline the rise and rationale behind these registry-based surveillance systems.